Glecaprevir/pibrentasvir (GLE/PIB) is a fixed-dose combination therapy approved for hepatitis C virus (HCV) that has expanded reach, reduced cost, and in certain patient populations, reduced HCV treatment duration, according to a recent review. The authors concluded:
- GLE/PIB is effective across all genotypes.
- GLE/PIB has been shown to be effective in HIV-infected patients, patients with chronic kidney disease (CKD), and Child-Pugh A-compensated cirrhosis.
- GLE/PIB is also effective for a shortened duration of 8 weeks in treatment-naïve non-cirrhotic patients.
Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. [Published online ahead of print May 29, 2018]. Hepatol Int. doi:10.1007/s12072-018-9873-y.
This Week's Must Reads
Must Reads in Hepatitis
Glecaprevir/Pibrentasvir Efficacy & Safety Assessed, J Hepatol; ePub 2018 Nov 23; D’Ambrosio, et al
HCV Infection Among Children & Young Persons, J Hepatol; ePub 2018 Nov 26; Modin, et al
HCV Patients with Limited Access to Antiviral Therapy, Dig Liver Dis; ePub 2018 Nov 29; Lens, et al
Progression in the Elimination of HCV Infection, PLoS One; ePub 2018 Dec 4; Juanbeltz, et al
Increased HCV Screening in Veteran Populations, Jt Comm J Qual Patient Saf; ePub 2018 Sep 25; Wray, et al